CN113577211A - Qibei body resistance strengthening granules and preparation method and application thereof - Google Patents
Qibei body resistance strengthening granules and preparation method and application thereof Download PDFInfo
- Publication number
- CN113577211A CN113577211A CN202111018594.5A CN202111018594A CN113577211A CN 113577211 A CN113577211 A CN 113577211A CN 202111018594 A CN202111018594 A CN 202111018594A CN 113577211 A CN113577211 A CN 113577211A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- body resistance
- qibei
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000005728 strengthening Methods 0.000 title claims abstract description 47
- 239000008187 granular material Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 15
- 239000002245 particle Substances 0.000 claims abstract description 15
- 241000711573 Coronaviridae Species 0.000 claims abstract description 8
- 241000255791 Bombyx Species 0.000 claims abstract description 6
- 241001489978 Eupolyphaga Species 0.000 claims abstract description 5
- 239000009636 Huang Qi Substances 0.000 claims abstract description 5
- 229940104299 cimicifugae rhizoma Drugs 0.000 claims abstract description 4
- 241000726221 Gemma Species 0.000 claims abstract description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 3
- 210000000582 semen Anatomy 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 33
- 235000013399 edible fruits Nutrition 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 208000015220 Febrile disease Diseases 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 10
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 10
- 235000008326 Trichosanthes anguina Nutrition 0.000 claims description 10
- 244000078912 Trichosanthes cucumerina Species 0.000 claims description 10
- 235000006533 astragalus Nutrition 0.000 claims description 10
- 244000144725 Amygdalus communis Species 0.000 claims description 9
- 240000005373 Panax quinquefolius Species 0.000 claims description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 9
- 240000006079 Schisandra chinensis Species 0.000 claims description 9
- 241000209140 Triticum Species 0.000 claims description 9
- 235000021307 Triticum Nutrition 0.000 claims description 9
- 235000020224 almond Nutrition 0.000 claims description 9
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 8
- 240000000249 Morus alba Species 0.000 claims description 8
- 235000008708 Morus alba Nutrition 0.000 claims description 8
- 206010037660 Pyrexia Diseases 0.000 claims description 8
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims description 8
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 8
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 7
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 7
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 244000307697 Agrimonia eupatoria Species 0.000 claims description 6
- 241000255789 Bombyx mori Species 0.000 claims description 6
- 241000935235 Fritillaria meleagris Species 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000004898 kneading Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 241001061264 Astragalus Species 0.000 claims description 5
- 241000045403 Astragalus propinquus Species 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 235000000125 common agrimony Nutrition 0.000 claims description 5
- 210000004233 talus Anatomy 0.000 claims description 5
- 241000202726 Bupleurum Species 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 241000906579 Actaea cimicifuga Species 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 235000006751 Platycodon Nutrition 0.000 claims description 3
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 240000006023 Trichosanthes kirilowii Species 0.000 claims description 3
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 229930189914 platycodon Natural products 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 244000236521 Bupleurum rotundifolium Species 0.000 claims description 2
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 claims description 2
- 241000675108 Citrus tangerina Species 0.000 claims description 2
- 235000005301 cimicifuga racemosa Nutrition 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 238000005469 granulation Methods 0.000 claims description 2
- 230000003179 granulation Effects 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 240000002948 Ophiopogon intermedius Species 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 13
- 206010067484 Adverse reaction Diseases 0.000 abstract description 5
- 230000006838 adverse reaction Effects 0.000 abstract description 5
- 239000003053 toxin Substances 0.000 abstract description 5
- 231100000765 toxin Toxicity 0.000 abstract description 5
- 230000007704 transition Effects 0.000 abstract description 4
- 230000001502 supplementing effect Effects 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 description 24
- 206010062717 Increased upper airway secretion Diseases 0.000 description 20
- 208000026435 phlegm Diseases 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 11
- 230000002159 abnormal effect Effects 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 244000197580 Poria cocos Species 0.000 description 7
- 235000008599 Poria cocos Nutrition 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 244000248557 Ophiopogon japonicus Species 0.000 description 6
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 6
- 240000003582 Platycodon grandiflorus Species 0.000 description 6
- 241000131329 Carabidae Species 0.000 description 5
- 235000008422 Schisandra chinensis Nutrition 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 241001278836 Agrimonia pilosa Species 0.000 description 4
- 235000000641 Agrimonia pilosa Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000009534 blood test Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 241000282461 Canis lupus Species 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000008517 radix Trichosanthis Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000006578 abscission Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000009666 routine test Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 241000206501 Actaea <angiosperm> Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 235000016993 Agrimonia Nutrition 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000218989 Trichosanthes Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Insects & Arthropods (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides Qibei body resistance strengthening particles and a preparation method and application thereof. The radix astragali and Bulbus Fritillariae Cirrhosae granule comprises radix astragali, radix Panacis Quinquefolii, radix Ophiopogonis, fructus Schisandrae chinensis, herba et Gemma Agrimoniae, folium Mori, semen Armeniacae amarum, fructus Trichosanthis, Bulbus Fritillariae Thunbergii, Trichosanthis radix, Bombyx Batryticatus, radix Platycodi, Poria, pericarpium Citri Tangerinae, Eupolyphaga Seu Steleophaga, cimicifugae rhizoma, bupleuri radix, rhizoma Polygoni Cuspidati, radix Glycyrrhizae Preparata, fructus Jujubae and fructus Tritici Levis. The Chinese medicinal preparation is designed for the convalescent stage of the novel coronavirus pneumonia, has the effects of supplementing qi and nourishing yin, strengthening body resistance and expelling toxin, helps patients to relieve symptoms, promotes stable transition of illness state, relieves sequelae, and reduces complications and adverse reactions.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, relates to a traditional Chinese medicine composition, and a preparation method and application thereof, and particularly relates to astragalus-fritillary body resistance strengthening particles, and a preparation method and application thereof.
Background
Viral exogenous febrile disease is commonly seen in influenza, acute suppurative tonsillitis and acute upper respiratory tract infection in modern medicine, has the characteristics of acute and serious illness, and the like, and is clinically manifested as fire-heat inflammation and hyperactivity of fire-heat symptoms such as high fever, red face and eyes, thirst with water, restlessness, constipation, dark urine, red tongue with yellow coating, rapid pulse and the like, and the symptoms of yin injury or inward invasion and degeneration caused by fire easily occur in the course of disease, and the critical adverse symptoms such as wind, bleeding and orifice blockage appear. The severe diseases include epidemic cerebrospinal meningitis, epidemic encephalitis B, epidemic hemorrhagic fever, toxic pneumonia, septicemia and the like. The typhoid and epidemic febrile diseases called by traditional Chinese medicine belong to the category of exogenous febrile diseases.
The new coronavirus pneumonia (Corona Virus Disease 2019, COVID-19) is called new coronavirus pneumonia for short, and is pneumonia caused by new coronavirus infection. The clinical manifestations of patients with pneumonia infected by the novel coronavirus are: the symptoms of fever, hypodynamia and dry cough are mainly manifested, and symptoms of upper respiratory tract such as nasal obstruction, watery nasal discharge and the like are rare, and the hypoxia and hypoxia state can occur. Approximately half of patients develop dyspnea after one week, and severe patients rapidly progress to acute respiratory distress syndrome, septic shock, refractory metabolic acidosis, and procoagulant dysfunction.
It is noted that the severe and critically ill patients may have moderate or low fever during their course, even without significant fever. Some patients have slight onset symptoms, but no fever, and recover after a week. The prognosis is good for most patients, and the disease is critical or even death for a few patients. The discharge criteria for new coronary pneumonia were negative for pharyngeal swab examination twice, no symptoms, normal body temperature, and normal CT followed by two weeks of isolation. The patient can be treated or recovered properly for the convalescent period of people who release the isolation and reach the discharge standard, so as to prevent the disease from repeating and reduce the harmful effect of the disease on the patient.
Traditional Chinese medicine accumulates abundant experience in treating viral exogenous febrile diseases, and the predecessors have left tens of thousands of prescriptions for treating various viral exogenous febrile diseases and a large number of documents recording the function and action of related medicines. The traditional Chinese medicine for treating viral exogenous febrile disease has the following advantages:
the effectiveness and safety of the traditional Chinese medicine for treating viral exogenous febrile disease are improved. The research in recent decades proves that the traditional Chinese medicine has definite curative effect on viral exogenous febrile diseases, and has great safety in the administration process because the traditional Chinese medicine is mainly natural medicine and is mostly used in a compound form, and the traditional Chinese medicine can play the roles of synergism and attenuation.
Secondly, the traditional Chinese medicine has better overall effect of treating viral exogenous febrile disease. The traditional Chinese medicine generally starts from integral adjustment when treating viral exogenous febrile diseases, plays a role in treatment by directly or indirectly killing pathogens, adjusting functions of an immune system, protecting an organism and reducing diseases and damage and the like, has the functions of multiple directions and multiple targets, often has the advantages that western medicines do not have, can block the course of disease, reduce symptoms, shorten the heating time and the hospitalization time, promote stable transition of the disease, reduce sequelae and reduce complications and adverse reactions of the western medicines. The combination of traditional Chinese medicine and western medicine can effectively integrate medical resources, reduce the death rate, reduce complications and reduce medical expenses.
Therefore, the traditional Chinese medicine composition for treating viral exogenous febrile disease, especially novel coronavirus pneumonia, has important clinical significance for preventing disease repetition and improving the resistance of patients.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide astragalus-fritillary strengthening particles and a preparation method and application thereof. The Qibei body resistance strengthening granule has the effects of tonifying qi and yin, strengthening body resistance and expelling toxin, is set for the convalescent period of the new coronary pneumonia, and is specially used for patients with incomplete remaining evil and deficient body resistance in the convalescent period.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the present invention provides a qi bei zheng granule, which is prepared from the following raw materials: radix astragali, radix Panacis Quinquefolii, radix Ophiopogonis, fructus Schisandrae chinensis, herba et Gemma Agrimoniae, folium Mori, semen Armeniacae amarum, fructus Trichosanthis, Bulbus Fritillariae Thunbergii, Trichosanthis radix, Bombyx Batryticatus, radix Platycodi, Poria, pericarpium Citri Tangerinae, Eupolyphaga Seu Steleophaga, cimicifugae rhizoma, bupleuri radix, rhizoma Polygoni Cuspidati, radix Glycyrrhizae Preparata, fructus Jujubae, and fructus Tritici Levis.
In the invention, the Qibei body resistance strengthening particles are arranged for the recovery period of the novel coronavirus pneumonia, the novel coronavirus pneumonia belongs to damp-heat pathogenic qi in traditional Chinese medicine, the damp-heat fetters the lung for a long time, the lung qi is greatly consumed, and the lung fluid is scorched, so that the astragalus, the American ginseng, the dwarf lilyturf tuber, the Chinese magnoliavine fruit and the hairyvein agrimony are used for tonifying the lung, supplementing qi and nourishing yin; meanwhile, the dampness and heat are steamed to turn into sticky phlegm and cough but not discharge, so the mulberry leaves are used for diffusing the lung, the almonds are used for lowering the lung, the snakegourd fruits, the thunberg fritillary bulbs and the trichosanthes roots are used for moistening the lung for eliminating phlegm, the stiff silkworms are used for eliminating stubborn phlegm, the platycodon roots are used for extracting lung qi, and the poria cocos is used for tonifying the spleen and removing dampness to eliminate phlegm as a source;
in addition, phlegm is the pathogenic factors of the body type, which can obstruct qi movement, and qi stagnation can lead to blood stasis, so it uses Chen Pi to move qi and Eupolyphaga Seu Steleophaga to activate blood; for damp-heat pathogen deeply lodged in the lung to form phlegm-phlegm embolism to wrap virus and cause yang recovery, Cimicifuga rhizome and Bupleurum root are used in combination with Astragalus root to expel toxin; the lung and the large intestine are exterior and interior to each other, so that the large intestine is communicated to facilitate the discharge of pathogenic qi in the lung, so the giant knotweed rhizome is used for slowly communicating the stool; considering that the patient has a long isolation period, fear in mind and low emotion, the emotion is relieved by the honey-fried licorice root, the Chinese date and the light wheat.
The Qibei body resistance strengthening granules provided by the invention start from integral adjustment, block the course of disease, relieve symptoms, shorten the fever time and the hospitalization time, promote the stable transition of the disease, relieve sequelae and reduce complications and adverse reactions.
It should be noted that the qi-bei body resistance strengthening granules in the present invention can exist in the form of granules, and the rest of the medicines including the decoction, pill, capsule and other dosage forms of the above traditional Chinese medicine formula are also within the protection scope of the present invention.
Preferably, the raw materials for preparing the Qibei Fuzheng granules comprise the components shown in the table 1 in parts by weight:
TABLE 1
In the invention, the astragalus has the functions of tonifying qi, tonifying lung and nourishing heart, and the weight parts can be 5 parts, 6 parts, 8 parts, 10 parts, 12 parts, 15 parts, 16 parts, 18 parts, 20 parts, 22 parts, 24 parts, 25 parts, 28 parts or 30 parts and the like.
The American ginseng can tonify qi and nourish yin, clear heat and promote fluid production, and the weight parts of the American ginseng can be 5 parts, 6 parts, 8 parts, 10 parts, 12 parts, 15 parts, 16 parts, 18 parts or 20 parts and the like.
The radix ophiopogonis can nourish yin, promote the production of body fluid, moisten lung and clear away heart-fire, and the weight parts of the radix ophiopogonis can be 5 parts, 6 parts, 8 parts, 10 parts, 12 parts, 15 parts, 16 parts, 18 parts or 20 parts and the like.
The schisandra fruit can astringe lung, nourish kidney, promote the production of body fluid, absorb sweat and astringe essence, and the weight portions of the schisandra fruit can be 5 portions, 6 portions, 8 portions, 10 portions, 12 portions, 15 portions, 16 portions, 18 portions or 20 portions, etc.
The agrimony can astringe to stop bleeding, check malaria, stop dysentery and detoxify, is commonly used for hemoptysis, hematemesis, nosebleed, malaria, debilitation and carbuncle swelling and the like, and can be 5 parts, 6 parts, 8 parts, 10 parts, 12 parts, 15 parts, 16 parts, 18 parts, 20 parts, 22 parts, 24 parts, 25 parts, 28 parts or 30 parts by weight.
The mulberry leaves can disperse wind and heat, clear away the lung-heat and moisten dryness, calm the liver and improve eyesight, cool blood and stop bleeding; the weight portion can be 5, 6, 8, 10, 12, 15, 16, 18 or 20 portions.
The almond can relieve cough and asthma and relax bowel, and the weight portion of the almond can be 5 portions, 6 portions, 8 portions, 10 portions, 12 portions, 15 portions, 16 portions, 18 portions or 20 portions, etc.
The snakegourd fruit is used for clearing heat and reducing phlegm, relieving chest stuffiness and resolving masses and relaxing bowel, and can be 5 parts, 6 parts, 8 parts, 10 parts, 12 parts, 15 parts, 16 parts, 18 parts, 20 parts, 21 parts, 22 parts, 24 parts or 25 parts by weight and the like.
The thunberg fritillary bulb can clear heat, resolve phlegm, relieve depression and dissipate stagnation, and the weight portion of the thunberg fritillary bulb can be 5 portions, 6 portions, 8 portions, 10 portions, 12 portions, 15 portions, 16 portions, 18 portions or 20 portions.
Trichosanthis radix has effects of clearing heat-fire, promoting fluid production to quench thirst, detumescence and expelling pus, and can be used for treating fever polydipsia, lung heat dry cough, internal heat diabetes, pyocutaneous disease and pyogenic infections; the weight portion can be 5, 6, 8, 10, 12, 15, 16, 18 or 20 portions.
The stiff silkworm can extinguish wind and stop spasm, dispel wind and relieve pain, and reduce phlegm and dissipate stagnation, and the weight parts of the stiff silkworm can be 5 parts, 6 parts, 8 parts, 10 parts, 12 parts, 15 parts, 16 parts, 18 parts or 20 parts, and the like.
The platycodon grandiflorum has the functions of dispersing lung and relieving sore throat, and eliminating phlegm and discharging pus, and the weight parts of the platycodon grandiflorum can be 5 parts, 6 parts, 8 parts, 10 parts, 12 parts, 15 parts, 16 parts, 18 parts or 20 parts, and the like.
The tuckahoe can promote diuresis, eliminate dampness, invigorate spleen and calm heart, and the weight portions of the tuckahoe can be 5, 6, 8, 10, 12, 15, 16, 18 or 20 portions.
The dried orange peel can regulate qi, invigorate spleen, dry dampness and resolve phlegm, and the weight portions can be 5, 6, 8, 10, 12, 15, 16, 18 or 20 portions.
The ground beetle is used for breaking blood and removing stasis and setting the sinew and bone, and the weight portions of the ground beetle can be 5 portions, 6 portions, 8 portions, 10 portions, 12 portions, 15 portions, 16 portions, 18 portions or 20 portions, etc.
Cimicifugae foetidae can release exterior and promote eruption, clear away heat and toxic material, and raise yang and lift sinking, and the parts by weight of the cimicifugae foetidae can be 3, 4, 5, 6, 7, 8, 9 or 10 parts and the like.
The bupleurum root, radix bupleuri, radix bupleuri, radix bupleuri, radix bupleuri, radix bupleuri, radix bupleuri, radix bupleuri, radix bupleuri, radix.
The giant knotweed rhizome has the functions of dispelling wind and promoting diuresis, eliminating stasis and relieving pain, relieving cough and reducing sputum, and the weight portions of the giant knotweed rhizome can be 5 portions, 6 portions, 8 portions, 10 portions, 12 portions, 15 portions, 16 portions, 18 portions, 20 portions, 21 portions, 22 portions, 24 portions or 25 portions, etc.
Prepared licorice root, radix Glycyrrhizae Praeparata, in parts by weight, is capable of tonifying spleen and qi, eliminating phlegm and stopping cough, and harmonizing the effects of the medicines, such as 5 parts, 6 parts, 8 parts, 10 parts, 12 parts, 15 parts, 16 parts, 18 parts or 20 parts.
The Chinese date has the functions of strengthening the middle-jiao and replenishing qi, and nourishing blood and tranquilization, and the weight portions of the Chinese date can be 5 portions, 6 portions, 8 portions, 10 portions, 12 portions, 15 portions, 16 portions, 18 portions or 20 portions, etc.
The light wheat can strengthen superficial resistance, stop sweating, tonify qi and remove heat, and the weight portion can be 5 portions, 6 portions, 8 portions, 10 portions, 12 portions, 15 portions, 16 portions, 18 portions, 20 portions, 22 portions, 24 portions, 25 portions, 28 portions or 30 portions, etc.
In a preferred embodiment of the present invention, the astragalus membranaceus is 20 to 30 parts by weight (e.g., 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, or 30 parts), the agrimonia pilosa is 20 to 30 parts by weight (e.g., 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, or 30 parts), and the blighted wheat is 20 to 30 parts by weight (e.g., 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, or 30 parts).
Preferably, the weight part of the whole snakegourd fruit is 10-20 parts (for example, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts or 10 parts and the like), and the weight part of the giant knotweed rhizome is 15-25 parts (for example, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts, 20 parts, 21 parts, 22 parts, 23 parts, 24 parts or 25 parts and the like).
Preferably, the cimicifuga foetida is 5 to 8 parts (e.g. 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts or 8 parts, etc.) by weight, and the bupleurum root is 5 to 8 parts (e.g. 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts or 8 parts, etc.).
As a preferable technical scheme of the invention, the raw materials for preparing the Qibei Fuzheng granules comprise the following components in parts by weight as shown in the following table 2:
TABLE 2
Components | Parts by weight/part | Components | Parts by weight/part | Components | Parts by weight/part |
Astragalus membranaceus | 30 | American ginseng | 10 | Ophiopogon japonicus | 10 |
Schisandra chinensis | 10 | Agrimonia pilosa Ledeb | 30 | Mulberry Leaves | 10 |
Almond | 10 | Whole snakegourd fruit | 20 | Bulbus Fritillariae Thunbergii | 10 |
Radix trichosanthis | 10 | Bombyx Batryticatus | 10 | Root of balloonflower | 10 |
Poria cocos (Schw.) wolf | 10 | Dried orange peel | 10 | Ground beetle | 10 |
Cimicifugae foetidae | 6 | Radix bupleuri | 6 | Giant knotweed rhizome | 15 |
Prepared licorice root | 10 | Chinese date | 10 | Blighted wheat | 30 |
Preferably, the astragalus-fritillary body resistance strengthening granules further comprise pharmaceutically acceptable auxiliary materials.
Preferably, the pharmaceutically acceptable auxiliary materials comprise any one or a combination of at least two of a binding agent, an antistaling agent, a flavoring agent or a disintegrating agent.
In a second aspect, the present invention also provides a preparation method of the qi-bei body resistance strengthening granule as described in the first aspect, the preparation method comprising:
mixing the components in the formula, adding water, decocting to obtain a decoction, filtering, concentrating to obtain an extract, and granulating the extract to obtain the Qibei body resistance strengthening granules.
As a preferred technical scheme of the invention, the method also comprises the step of grinding the components in the formula into powder before mixing.
Preferably, the number of times of decocting with water is 1-3 (for example, 1, 2 or 3 times), and the time of decocting with water for each time is 30 min-100 min, for example, 30min, 40min, 50min, 60min, 70min, 80min, 90min or 100min, etc.
Preferably, the concentration is to concentrate the obtained filtrate into an extract with a relative density of 1.30-1.35 (for example, 1.30, 1.31, 1.32, 1.33, 1.34 or 1.35);
preferably, the granulation method comprises: mixing the extract with binder, kneading, sieving, and drying to obtain granule.
Preferably, the binder comprises any one or a combination of at least two of sucrose, dextrin or starch.
As a preferred technical scheme of the invention, the preparation method comprises the following steps:
(1) mixing astragalus, American ginseng, dwarf lilyturf tuber, Chinese magnoliavine fruit, hairyvein agrimony, mulberry leaf, almond, snakegourd fruit, thunberg fritillary bulb, mongolian snakegourd root, stiff silkworm, platycodon root, Indian buead, tangerine peel, ground beeltle, largetrifolioliolious bugbane rhizome, Chinese thorowax root, giant knotweed rhizome, honey-fried licorice root, Chinese date and light wheat according to a formula amount, and adding water for decocting for 3 times, wherein the decocting time is 30-100 min each time;
(2) and combining the obtained decoctions, filtering, concentrating the filtrate into an extract with the relative density of 1.30-1.35, adding an adhesive, kneading, sieving, drying, and preparing the astragalus-fritillary body resistance strengthening granules.
In a third aspect, the invention provides the use of the astragalus-fritillary strengthening granules in the first aspect in preparing a medicine for treating exogenous febrile disease.
Preferably, the exogenous fever includes a novel coronary pneumonia.
The recitation of numerical ranges herein includes not only the above-recited values, but also any values between any of the above-recited numerical ranges not recited, and for brevity and clarity, is not intended to be exhaustive of the specific values encompassed within the range.
Compared with the prior art, the invention has the beneficial effects that:
the Qibei body resistance strengthening granules are used for treating the convalescent stage of the new coronary pneumonia, and have the effects of supplementing qi and nourishing yin, strengthening body resistance and expelling toxin. Wherein, the astragalus, the American ginseng, the dwarf lilyturf tuber, the Chinese magnoliavine fruit and the hairyvein agrimonia herb tonify the lung, tonify qi and nourish yin, and are mainly used for treating that damp-heat evil qi is chronically confined in the lung, the lung qi is greatly consumed and the lung fluid is burned; the mulberry leaf is used for ventilating the lung, the almond is used for lowering the lung, the snakegourd fruit, the thunberg fritillary bulb and the mongolian snakegourd root are used for moistening the lung and reducing phlegm, the stiff silkworm is used for dissolving stubborn phlegm, the platycodon grandiflorum is used for expelling lung qi, and the poria cocos is used for tonifying spleen and removing dampness, so that the source of phlegm is removed, and the main treatment is that damp-heat is evaporated, the phlegm is converted into sticky phlegm and the cough cannot be produced; pericarpium Citri Tangerinae is used for promoting circulation of qi, Eupolyphaga Seu Steleophaga is used for promoting blood circulation, cimicifugae rhizoma and bupleuri radix are used together with radix astragali for expelling toxin, rhizoma Polygoni Cuspidati is used for relieving constipation, and radix Glycyrrhizae Preparata, fructus Jujubae and fructus Tritici Levis are used for relieving emotion; the components in the Qibei body resistance strengthening granule cooperate with each other, so that the clinical symptoms of patients in the convalescent period of exogenous febrile diseases represented by new coronary pneumonia can be improved, and medical help is provided for the rehabilitation of the patients.
Meanwhile, the preparation method of the Qibei body resistance strengthening granules provided by the invention can fully extract the effective components in the raw materials and ensure the drug effect of the raw materials, and the traditional Chinese medicine composition is prepared into the granules by the method, so that the granules are more convenient for patients to take.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
The following examples do not specify particular techniques or conditions, according to the techniques or conditions described in the literature in the field, or according to the product specifications.
The reagents and instruments used in the following examples are not indicated by manufacturers, and are all conventional products commercially available from normal sources.
Example 1
The embodiment provides Qibei body resistance strengthening granules, which comprise the following components in percentage by weight as shown in the following table 3:
TABLE 3
The preparation method of the Qibei body resistance strengthening granules comprises the following steps:
(1) mixing the above Chinese medicinal materials according to formula ratio, decocting in water for 3 times, each time for 60 min;
(2) mixing the obtained decoctions, filtering, concentrating the filtrate to obtain extract with relative density of 1.35, adding sucrose 2g and dextrin 1g, kneading, sieving, and drying to obtain QIBEIFUZHENG granule.
Example 2
The embodiment provides Qibei body resistance strengthening granules, which comprise the following components in percentage by weight as shown in the following table 4:
TABLE 4
Components | Weight/g | Components | Weight/g | Components | Weight/g |
Astragalus membranaceus | 20 | American ginseng | 10 | Ophiopogon japonicus | 10 |
Schisandra chinensis | 10 | Agrimonia pilosa Ledeb | 20 | Mulberry Leaves | 10 |
Almond | 10 | Whole snakegourd fruit | 15 | Bulbus Fritillariae Thunbergii | 5 |
Radix trichosanthis | 5 | Bombyx Batryticatus | 10 | Root of balloonflower | 10 |
Poria cocos (Schw.) wolf | 10 | Dried orange peel | 10 | Ground beetle | 10 |
Cimicifugae foetidae | 3 | Radix bupleuri | 10 | Giant knotweed rhizome | 10 |
Prepared licorice root | 5 | Chinese date | 5 | Blighted wheat | 20 |
The preparation method of the Qibei body resistance strengthening granules comprises the following steps:
(1) mixing the above Chinese medicinal materials according to formula ratio, decocting in water for 2 times, each time for 80 min;
(2) mixing the obtained decoctions, filtering, concentrating the filtrate to obtain extract with relative density of 1.30, adding sucrose 1.5g and starch 1g, kneading, sieving, and drying to obtain QIBEIFUZHENG granule.
Example 3
The embodiment provides Qibei body resistance strengthening granules, which comprise the following components in the following table 5:
TABLE 5
Components | Weight/g | Components | Weight/g | Components | Weight/g |
Astragalus membranaceus | 30 | American ginseng | 10 | Ophiopogon japonicus | 20 |
Schisandra chinensis | 10 | Agrimonia pilosa Ledeb | 5 | Mulberry Leaves | 10 |
Almond | 10 | Whole snakegourd fruit | 15 | Bulbus Fritillariae Thunbergii | 5 |
Radix trichosanthis | 5 | Bombyx Batryticatus | 20 | Root of balloonflower | 10 |
Poria cocos (Schw.) wolf | 20 | Dried orange peel | 10 | Ground beetle | 20 |
Cimicifugae foetidae | 10 | Radix bupleuri | 3 | Giant knotweed rhizome | 10 |
Prepared licorice root | 5 | Chinese date | 5 | Blighted wheat | 30 |
The preparation method of the Qibei body resistance strengthening granules comprises the following steps:
(1) mixing the above Chinese medicinal materials according to formula ratio, decocting in water for 2 times, each time for 80 min;
(2) mixing the decoctions, and filtering to obtain QIBEIFENGZHENG decoction.
Evaluation of safety
The subjects were treated with the astragalus-bei strengthening granules prepared in example 1 for two weeks, with 10g each time, 3 times daily, and without other similar drugs.
During the course of treatment, the subject was observed for changes in the following indices, before and after treatment, respectively, including: the laboratory checks the routine of blood, urine and stool, the functions of liver and kidney and the incidence rate of adverse reactions.
1: routine blood examination
In this example, a total of 71 patients completed routine blood tests in and out of the group; among them, 28 patients with abnormal entry blood routine test and 27 patients with abnormal exit blood routine test.
Single patient contextual comparisons: statistical analysis is carried out on blood routine examination data of 71 patients with 8 patients with normal group entry blood routine indexes and abnormal group exit blood routine indexes, and the results are shown in the following table 6 by using a T test method:
TABLE 6
Paired sample test data are shown in table 7 below:
TABLE 7
As can be seen from the above table, the change P value of each group of examination indexes is not less than 0.05 before and after treatment, and the difference has no statistical significance; the qi-bei body resistance strengthening granule is considered to have no influence on the conventional blood indexes of patients.
2. Blood biochemical examination and analysis
In this example, 69 patients completed biochemical blood tests of group entry and group exit, wherein 10 patients were abnormal in biochemical blood test of group entry and 12 patients were abnormal in biochemical blood test of group exit.
Single patient contextual comparisons: the biochemical index of the incoming blood is normal, and the biochemical index of the outgoing blood is abnormal in 5 cases, the blood biochemical examination data of 69 patients are statistically analyzed, and the results are shown in the following table 8 by using a T test method:
TABLE 8
Paired sample test data is shown in table 9 below:
TABLE 9
As can be seen from the above table, the comparison P values before and after urea nitrogen in the biochemical indexes before and after treatment are all less than 0.05, and the difference has statistical significance. The average value of urea nitrogen after treatment is 5.21 in the normal range of the index, and the comparison difference between the other indexes has no statistical significance; the astragalus-fritillary body resistance strengthening granules are considered to have no adverse effect on the blood biochemical indexes of patients.
3. Routine examination and analysis of urine
In this example, a total of 67 patients completed routine urine examinations into and out of the group. Among them, 31 patients with abnormal test of group urine routine and 36 patients with abnormal test of group urine routine are selected.
Single patient contextual comparisons: the urine routine examination data of 67 patients were statistically analyzed for 11 patients with normal index of the entering urine and abnormal index of the exiting urine, and the results of the T test were shown in table 10 below:
watch 10
Paired sample test data are shown in table 11 below:
TABLE 11
As can be seen from the above table, the conventional indexes of urine P are all more than or equal to 0.05, and the difference has no statistical significance.
4. Convenient routine analysis
The routine examination of the patients in the group and the patients out of the group are completely completed by 15 patients, and the routine examination of the patients in the group and the patients out of the group of 15 patients has no abnormality.
Through the analysis of the blood routine, the urine routine, the stool routine and the liver and kidney functions, after the test subject takes the astragalus-fritillary body strengthening particles, various functions of the body of the test subject are not obviously affected, and the abnormal examination items in the experimental process can be caused by diseases or body differences of the test subject;
therefore, the safety evaluation experiment proves that the Qibei body resistance strengthening granules provided by the invention have the advantages that each component follows the compatibility principle of 'monarch, minister, assistant and guide', no obvious adverse reaction occurs, and the granules have higher safety for patients, particularly patients with deficiency of both qi and yin in the new coronary rehabilitation period.
Evaluation of traditional Chinese medicine syndromes
In order to further verify the treatment effect of the Qibei body resistance strengthening particles on patients in the new coronary rehabilitation period, 101 patients are taken as treatment objects in a performance test.
There were 12 total abscissions during the experiment, the reasons for abscission were: patient quit due to personal affair initiative, patient miss visit due to non-explanation reason or patient quit due to violation of experimental scheme, etc.
Subjects were treated with the astragalus-bei strengthening particles prepared in example 1 for two weeks, with 10g each, 3 times daily, and without other similar drugs. The clinical symptom change condition of the subject is observed according to the clinical research guiding principle of new traditional Chinese medicine based on the reduction percentage of the syndrome score.
The traditional Chinese medicine syndromes mainly observe major symptoms and minor symptoms, and specifically comprise:
the main symptoms are: cough, shortness of breath, weakness;
the secondary symptoms are as follows: no phlegm or little and sticky phlegm, sweating, dry mouth or throat, poor appetite, fullness and distention, loose stool or constipation, and the like, and the change of the qi-yin syndrome with unexhausted pathogenic factors;
according to the scoring of the clinical research guideline of new traditional Chinese medicine, the change of clinical symptoms is observed:
a. and (3) judging the curative effect of the main symptoms: cough, expectoration, shortness of breath and other symptoms.
The results are shown in table 12 below:
TABLE 12
Item | Disappearance (example) | Improvement (example) | Invalid (example) | Total effective rate |
Main index/person | 2 | 74 | 13 | 85.4% |
Wherein, disappearance: symptom disappeared, score 0;
improvement: symptom relief, score reduction, but not 0;
and (4) invalidation: symptoms were not reduced or exacerbated, and scores were not reduced.
As can be seen from the above table, after 2 weeks using the granules provided by the present invention, the principal symptoms of 2 patients disappeared, the principal symptoms of 76 patients improved, and the total effective rate was 85.7%.
b. Evaluation of traditional Chinese medicine syndrome therapeutic effect (integral ratio method)
The main outcome indexes of the clinical curative effect are analyzed, and the method specifically comprises the following steps:
and (3) clinical control: the integral improvement rate of the syndrome after treatment is more than or equal to 95 percent;
the effect is shown: the syndrome integral improvement rate after treatment is more than or equal to 70 percent and less than 95 percent;
improvement: the syndrome integral improvement rate after treatment is more than or equal to 30 percent and less than 70 percent;
and (4) invalidation: the improvement rate of the syndrome score after treatment is less than 30 percent.
In the test procedure, the qi bei body resistance strengthening granules are administered for two weeks, based on the percentage reduction of the syndrome score, and the results are shown in the following table 13:
watch 13
Time | Control rate/%) | Significant efficiency/%) | Effective rate% | Non efficiency/%) |
One week later | 0 | 2.25 | 49.44 | 48.31 |
After two weeks | 2.25 | 24.72 | 51.69 | 21.35 |
After the astragalus-fritillary body resistance strengthening particles are used for two weeks, the symptoms of patients are obviously relieved, the control rate, the significant efficiency and the effective rate can reach 78.66%, and the effect is better.
In conclusion, the astragalus-baibei body resistance strengthening granules comprise a plurality of natural medicines, can achieve the effects of synergism and attenuation, have higher safety in the medication process, and the components in the traditional Chinese medicine formula are cooperated to reduce the symptoms of patients, promote the stable transition of the state of an illness and reduce sequelae.
The applicant declares that the above description is only a specific embodiment of the present invention, but the scope of the present invention is not limited thereto, and it should be understood by those skilled in the art that any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are within the scope and disclosure of the present invention.
Claims (10)
1. The astragalus-fritillary body resistance strengthening particles are characterized by being prepared from the following raw materials:
radix astragali, radix Panacis Quinquefolii, radix Ophiopogonis, fructus Schisandrae chinensis, herba et Gemma Agrimoniae, folium Mori, semen Armeniacae amarum, fructus Trichosanthis, Bulbus Fritillariae Thunbergii, Trichosanthis radix, Bombyx Batryticatus, radix Platycodi, Poria, pericarpium Citri Tangerinae, Eupolyphaga Seu Steleophaga, cimicifugae rhizoma, bupleuri radix, rhizoma Polygoni Cuspidati, radix Glycyrrhizae Preparata, fructus Jujubae and fructus Tritici Levis.
3. the astragalus-fritillary body resistance strengthening granules as claimed in claim 1 or 2, wherein the astragalus membranaceus accounts for 20-30 parts by weight, the agrimony accounts for 20-30 parts by weight, and the blighted wheat accounts for 20-30 parts by weight;
preferably, the weight parts of the whole snakegourd fruit are 10-20 parts, and the weight parts of the giant knotweed rhizome are 15-25 parts;
preferably, the cimicifugae foetidae is 5-8 parts by weight, and the bupleurum is 5-8 parts by weight.
5. the Qibei body resistance strengthening particle according to any one of claims 1 to 4, further comprising a pharmaceutically acceptable excipient;
preferably, the pharmaceutically acceptable auxiliary materials comprise any one or a combination of at least two of a binding agent, an antistaling agent, a flavoring agent or a disintegrating agent.
6. A method for preparing the Qibei body resistance strengthening particle as claimed in any one of claims 1 to 5, wherein the preparation method comprises the following steps:
mixing the components in the formula, adding water, decocting to obtain a decoction, filtering, concentrating to obtain an extract, and granulating the extract to obtain the Qibei body resistance strengthening granules.
7. The method of claim 6, further comprising the step of grinding the components of the formulation into a powder prior to mixing;
preferably, the number of times of water adding and decocting is 1-3, and the time of water adding and decocting each time is 30-100 min.
8. The method of claim 6 or 7, wherein the concentrating is: concentrating the obtained filtrate into an extract with the relative density of 1.30-1.35;
preferably, the granulation method comprises: mixing the extract with an adhesive, kneading, sieving, and drying to obtain granules;
preferably, the binder comprises any one or a combination of at least two of sucrose, dextrin or starch.
9. The method according to any one of claims 6 to 8, characterized by comprising the steps of:
(1) mixing astragalus, American ginseng, dwarf lilyturf tuber, Chinese magnoliavine fruit, hairyvein agrimony, mulberry leaf, almond, snakegourd fruit, thunberg fritillary bulb, mongolian snakegourd root, stiff silkworm, platycodon root, Indian buead, tangerine peel, ground beeltle, largetrifolioliolious bugbane rhizome, Chinese thorowax root, giant knotweed rhizome, honey-fried licorice root, Chinese date and light wheat according to a formula amount, and adding water for decocting for 3 times, wherein the decocting time is 30-100 min each time;
(2) and combining the obtained decoctions, filtering, concentrating the filtrate into an extract with the relative density of 1.30-1.35, adding an adhesive, kneading, sieving, drying, and preparing the astragalus-fritillary body resistance strengthening granules.
10. The use of the Qibei Fuzheng granule of any one of claims 1 to 5 in the preparation of a drug for treating exogenous febrile disease;
preferably, the exogenous fever includes a novel coronavirus pneumonia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111018594.5A CN113577211A (en) | 2021-09-01 | 2021-09-01 | Qibei body resistance strengthening granules and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111018594.5A CN113577211A (en) | 2021-09-01 | 2021-09-01 | Qibei body resistance strengthening granules and preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113577211A true CN113577211A (en) | 2021-11-02 |
Family
ID=78240825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111018594.5A Pending CN113577211A (en) | 2021-09-01 | 2021-09-01 | Qibei body resistance strengthening granules and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113577211A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111249391A (en) * | 2020-03-26 | 2020-06-09 | 北京中医药大学第三附属医院 | Traditional Chinese medicine composition for convalescent period of exogenous febrile disease and preparation method and application thereof |
CN112007139A (en) * | 2020-09-25 | 2020-12-01 | 漯河市第一人民医院 | Astragalus-cassia twig-poria traditional Chinese medicine mixture for treating cold-dampness lung-stasis type viral pneumonia |
-
2021
- 2021-09-01 CN CN202111018594.5A patent/CN113577211A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111249391A (en) * | 2020-03-26 | 2020-06-09 | 北京中医药大学第三附属医院 | Traditional Chinese medicine composition for convalescent period of exogenous febrile disease and preparation method and application thereof |
CN112915155A (en) * | 2020-03-26 | 2021-06-08 | 北京中医药大学第三附属医院 | Traditional Chinese medicine composition for convalescent period of exogenous febrile disease and preparation method and application thereof |
CN112007139A (en) * | 2020-09-25 | 2020-12-01 | 漯河市第一人民医院 | Astragalus-cassia twig-poria traditional Chinese medicine mixture for treating cold-dampness lung-stasis type viral pneumonia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111265616B (en) | Traditional Chinese medicine composition and application thereof in prevention and treatment of viral pneumonia | |
CN112915155B (en) | Traditional Chinese medicine composition for convalescent period of exogenous febrile disease and preparation method and application thereof | |
CN113521232B (en) | A Chinese medicinal composition containing Atractylodis rhizoma | |
CN113616747A (en) | Traditional Chinese medicine composition for rehabilitation of infectious diseases and application thereof | |
CN107648468B (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and application thereof | |
CN101468089A (en) | Chinese medicinal composition for diffusing lung, relieving exterior syndrome, suppressing cough and reducing phlegm and preparation method thereof | |
CN110193061B (en) | Preparation and application of traditional Chinese medicine granules for treating or preventing children influenza virus infection | |
CN113350429B (en) | Traditional Chinese medicine composition for preventing and treating African swine fever disease as well as preparation method and application thereof | |
CN115919963A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating novel coronavirus infection | |
CN113577211A (en) | Qibei body resistance strengthening granules and preparation method and application thereof | |
CN114712478A (en) | Traditional Chinese medicine composition and preparation for treating intestinal diseases and preparation method thereof | |
CN105327115A (en) | Phellinus linteus catharsis formula for prevention and cure of type II diabetes and preparation process thereof | |
CN115869375B (en) | Traditional Chinese medicine composition for clearing heat and dispelling wind as well as preparation method and application thereof | |
CN105435162B (en) | Traditional Chinese medicine composition for treating allergic rhinitis, preparation method and traditional Chinese medicine preparation | |
CN104189562A (en) | Sugarcane, folium mori and platycodon grandiflorum granules for treating cough post influenza | |
CN116251141B (en) | Traditional Chinese medicine composition for dispelling wind-cold and preparation method and application thereof | |
CN116920061B (en) | Traditional Chinese medicine composition for treating hyperglycemia and preparation method thereof | |
CN113274470B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia | |
CN117257866B (en) | Traditional Chinese medicine composition for treating community-acquired pneumonia and application thereof | |
CN108888731B (en) | Pharmaceutical composition for relieving cough and reducing sputum | |
CN104758346A (en) | Medicine for treating migraine, as well as preparation method and preparation of medicine | |
CN102716371A (en) | Traditional Chinese medicine composition for curing chronic cough as well as preparation method and usages thereof | |
CN118267445A (en) | Traditional Chinese medicine composition for treating severe pneumonia and application thereof | |
CN118717901A (en) | A Chinese medicinal preparation for relieving exterior syndrome and clearing away internal heat | |
CN118697832A (en) | Ginseng root formula for treating renal hematuria and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211102 |
|
RJ01 | Rejection of invention patent application after publication |